Literature DB >> 175100

Urinary cyclic adenosine monophosphate in young adults and elderly subjects.

C Gennari, M Galli, M Montagnani.   

Abstract

The 24-hour urinary excretion of cyclic 3',5'-adenosine monophosphate (cAMP) was measured by a protein-binding assay in 55 healthy volunteers (aged 20-35 yr) and in 30 hospitalized elderly subjects (aged 70-93 yr). In the older subjects the mean 24-hour cAMP excretion was significantly lower; the correlation between cAMP excretion and age demonstrated a progressive decrease from the age of 70 to the tenth decade. Many different factors could account for the reduced urinary cAMP excretion in elderly subjects: a decline in the reactivity of the adenyl cyclase-cAMP system related to physiological ageing; reduced physical activity; a reduction in the glomerular filtration rate or decreased production of cAMP by tubular cells in the senile kidney.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 175100      PMCID: PMC475949          DOI: 10.1136/jcp.29.1.69

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.

Authors:  D F DAVIES; N W SHOCK
Journal:  J Clin Invest       Date:  1950-05       Impact factor: 14.808

2.  Primary hyperparathyroidism: clinical and biochemical features.

Authors:  L E Mallette; J P Bilezikian; D A Heath; G D Aurbach
Journal:  Medicine (Baltimore)       Date:  1974-03       Impact factor: 1.889

3.  Effect of upright posture and isoproterenol infusion on cyclic adenosine monophosphate excretion in control subjects and patients with labile hypertension.

Authors:  P Hamet; O Kuchel; J Genest
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

4.  Urinary excretion of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate.

Authors:  F Murad; C Y Pak
Journal:  N Engl J Med       Date:  1972-06-29       Impact factor: 91.245

5.  Newborn urinary cyclic AMP and developmental renal responsiveness to parathyroid hormone.

Authors:  L G Linarelli
Journal:  Pediatrics       Date:  1972-07       Impact factor: 7.124

6.  Factors influencing the urinary excretion of 3',5'-adenosine monophosphate in humans.

Authors:  A L Taylor; B B Davis; L G Pawlson; J B Josimovich; D H Mintz
Journal:  J Clin Endocrinol Metab       Date:  1970-03       Impact factor: 5.958

7.  Exercise and urinary excretion of cyclic A.M.P.

Authors:  D Eccleston; R Loose; I A Pullar; R F Sugden
Journal:  Lancet       Date:  1970-09-19       Impact factor: 79.321

8.  Parathyroid function and the renal excretion of 3'5'-adenylic acid.

Authors:  L R Chase; G D Aurbach
Journal:  Proc Natl Acad Sci U S A       Date:  1967-08       Impact factor: 11.205

9.  Sources of cyclic nucleotides in plasma.

Authors:  R E Wehmann; L Blonde; A L Steiner
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine.

Authors:  R W BUTCHER; E W SUTHERLAND
Journal:  J Biol Chem       Date:  1962-04       Impact factor: 5.157

View more
  3 in total

1.  Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy.

Authors:  C Gennari; G Francini; M Galli; F Lore
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

2.  Seasonal variation in urinary excretion of cyclic AMP in healthy people.

Authors:  C Gennari; F Loré; M Galli; I D D'Amore; G Francini
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

3.  The 24-h urinary cyclic adenosine 3', 5' monophosphate/creatinine ratio: an useful approach to the diagnosis of parathyroid disorders and function.

Authors:  A Caniggia; R Nuti; M Galli
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.